Full Press Release Details
Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health
next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities
for remote endovascular procedures
Mass., April 29, 2024 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular
Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed,
which demonstrated the LIBERTY System's technical capabilities and outlines potential future applications in a range of endovascular
interventions. The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics between remote
centers by utilizing the LIBERTY System. The agreement with Corewell Health includes the right to mutually evaluate the LIBERTY System
for remote procedures and it is being led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac
Cath Lab at Corewell Health in Grand Rapids, Michigan.
Madder and colleagues have recently published an abstract reflecting the results of the first phase of the aforementioned collaboration
in the Journal of the American College of Cardiology: Cardiovascular Interventions, highlighting the Technical Success of Coronary Guidewire
and Stent Delivery Using a Novel Miniaturized Robotic System in a Pre-Clinical Study.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and
physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System's remote operation has
the potential to be the first system to democratize endovascular interventional procedures.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY
Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether
the Company succeeds in obtaining FDA approval to commence its pivotal study in humans, any failure or inability to recruit physicians
and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, ,
disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering
uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot
Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web
site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required